Home
Science
Mocravimod
Acute Myeloid Leukemia & Hematopoietic Cell Transplantation
Our Pipeline
Privacy Policy
Clinical Trial
Press
About
Our Leadership Team
Advisory Board
Investors
Our Partners
ESG Report
Contact
Select Page
mocravimod
by
admin
|
Jun 16, 2022
Search for:
Recent Posts
Priothera Appoints Experienced Biotech Executive, Dr Nigel Clark, as Chief Business Officer to Lead Strategic Partnering for Mocravimod
Clinical assessment of mocravimod as a victim of drug–drug interactions via CYP3A4 metabolism and transporters
Priothera accélère sur son traitement des cancers hématologiques
Priothera accélère sur son traitement des cancers hématologiques
Priothera, la start-up Florent de Saint-Louis qui se rêve licorne
Recent Comments
Priothera to start Phase IIb/III trial of acute myeloid leukaemia therapy
on
Priothera Receives FDA clearance of Investigational New Drug (IND)
FDA grants orphan drug designation to mocravimod for acute myeloid leukemia - Healio - The Online Chemists
on
Priothera – FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)
Recent Comments